Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma

BACKGROUND: Metastatic Merkel cell carcinoma (mMCC) is an aggressive neuroendocrine malignancy of the skin with a poor prognosis. Immune checkpoint inhibitors (ICIs) have shown substantial efficacy and favorable safety in clinical trials. METHODS: Medical records of patients (pts) with mMCC treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Weppler, Alison M, Pattison, Andrew, Bhave, Prachi, De Ieso, Paolo, Raleigh, Jeanette, Hatzimihalis, Athena, Gill, Anthony J, Balachander, Shiva, Callahan, Jason, Chua, Margaret, Au-Yeung, George, McArthur, Grant A, Hicks, Rodney J, Tothill, Richard W, Sandhu, Shahneen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566424/
https://www.ncbi.nlm.nih.gov/pubmed/33060145
http://dx.doi.org/10.1136/jitc-2020-000700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566424/
https://www.ncbi.nlm.nih.gov/pubmed/33060145
http://dx.doi.org/10.1136/jitc-2020-000700

Ejemplares similares